---
title: "Calidi Gains on Company Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293352444.md"
description: "Calidi Biotherapeutics (NYSE: CLDI) shares rose 3.3% to $16.52 following a company update highlighting 2026 progress. Key developments include successful FDA pre-IND meetings for CLD-401, proof-of-concept data for In Situ TCEs, and board additions. The company also reported reduced debt and G&A expenses by approximately $1M in Q1 2026, emphasizing continued cost-cutting efforts to fund pipeline advancement."
datetime: "2026-07-21T13:50:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293352444.md)
  - [en](https://longbridge.com/en/news/293352444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293352444.md)
---

# Calidi Gains on Company Update

Calidi Biotherapeutics, Inc. (NYSE: CLDI) shares were positive Tuesday. The San Diego-based concern, a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today recapped 2026 successes to date and provided an update on the Company’s upcoming milestones.

“Calidi continues to execute on its goal of bringing its RedTail platform to the clinic and expanding the utility of this groundbreaking technology,” said Calidi CEO Eric Poma, “We have had productive discussions with the FDA that support our strategy and timeline for CLD-401 IND filing and we continue to expand the reach of RedTail with the development of in situ TCEs.”

This year’s first half included:

Successful pre-IND meeting with FDA with agreement on pharmacology, toxicology, CMC, and phase I protocol strategy for CLD-401 phase I trial

In Situ TCEs have the potential to overcome current limitations around T-cell engagers in solid tumors by their ability to deliver high levels of a TCE in situ while simultaneously activating T-cells in the tumor microenvironment. Proof-of-concept data presented in 2026 underscore this potential

Strengthened the Board of Directors with the addition of Corsee Sanders, Ph.D.

Reduced debt and G&A expenses by approximately $1M in 1Q26 over 1Q25. Company will maintain a continued focus on cost cutting to ensure sufficient capital to advance pipeline.

CLDI shares grabbed 52 cents, or 3.3%, to $16.52

### Related Stocks

- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)

## Related News & Research

- [Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program](https://longbridge.com/en/news/293929420.md)
- [Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board](https://longbridge.com/en/news/293337933.md)
- [Johnson & Johnson Innovation to host virtual pitch session for oral peptide delivery challenge finalists](https://longbridge.com/en/news/293471519.md)
- [Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | APVO Stock News](https://longbridge.com/en/news/293930096.md)
- [HM Exploration Commences Optical & Acoustic Televiewer Program at the Lewis Pilley's Project | HMEXF Stock News](https://longbridge.com/en/news/293715367.md)